Precision medicine requires finding people at a high risk of disease.
We used >3,000 proteins to develop sparse models for prediction of future risk of 218 diseases using #EHRs and #MachineLearning in @uk_biobank.
https://t.co/N4QDqgUWwp
https://t.co/YmBnZAENsO
Precision medicine requires finding people at a high risk of disease.
We used >3,000 proteins to develop sparse models for prediction of future risk of 218 diseases using #EHRs and #MachineLearning in @uk_biobank.
https://t.co/N4QDqgUWwp
https://t.co/YmBnZAENsO
We make our results available through our webserver (https://t.co/qKjK9jhJ6q) to visualise the potential benefit of #proteomic screening in a Bayesian framework.
Outstanding scientists elected to EMBO Membership: in EMBO’s 60th anniversary year, 100 new members and 20 associate members join the community
https://t.co/eHCoXY0ynR
Outstanding scientists elected to EMBO Membership: in EMBO’s 60th anniversary year, 100 new members and 20 associate members join the community
https://t.co/eHCoXY0ynR
People with multiple diseases are prone to severe #Covid_19 and #LongCovid but which ones are most important and who did we miss?
We gathered >1,400 diseases in @uk_biobank using #EHRs to find out and triangulate with #Genetics
https://t.co/uKHqxpRFQt
However, known risk loci for #COVID_19 seem to behave oddly, ie., not always agree in direction of effect on highly related disease.
TYK2 challenges the popular genetically informed repurposing story of baricitinib (JAK-target); points to *adverse* effects of TYK2 inhibitors